CIK 0001658551 · Non-accelerated filer<br>Smaller reporting company
Amylyx Pharmaceuticals, Inc.
Sign in to watch- Ticker
- AMLX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 464600503
- Phone
- 617-682-0917
- Business address
- 55 CAMBRIDGE PARKWAY, SUITE 6W, CAMBRIDGE, MA, 02142
- 144 Insider Sale of Securities
- 144 Insider Sale of Securities
- 144 Insider Sale of Securities
- SCHEDULE 13G Stake Statement of Beneficial Ownership
- SCHEDULE 13G/A Stake Statement of Beneficial Ownership
- 4 Open-market sale Co-Chief Executive Officer sold 138,167 shares at an average $13.59 ($1,878,094)
- 4 Open-market sale Co-Chief Executive Officer sold 138,188 shares at an average $13.59 ($1,877,570)
- 144 Insider Sale of Securities
- 144 Insider Sale of Securities
- 144 Insider Sale of Securities
- 144 Insider Sale of Securities
- 4 Gift Director gave 17,780 shares (gift)
- 4 Open-market sale Chief Financial Officer sold 3,326 shares at $11.11 ($36,954)
- 4 Open-market sale Co-Chief Executive Officer sold 7,715 shares at $11.09 ($85,596)
- 4 Open-market sale Co-Chief Executive Officer sold 7,715 shares at $11.09 ($85,589)
- 8-K Event Regulation FD disclosure · Other events
- 144 Insider Sale of Securities
- 144 Insider Sale of Securities
- 144 Insider Sale of Securities
- 4 Open-market buy Director bought 8,100 shares at $12.45 ($100,845)
Page 5 of 23 · 446 filings